After Viking Therapeutics (VKTX) announced topline results from its Phase 2 trial of oral VK2735 for weight loss, H.C. Wainwright analyst Joseph Pantginis views the weight loss results as “encouraging” and the tolerability profile as “something that can be optimized.” The firm highlights a few contributing factors that it believes may be driving the initial negative reaction in the stock, including some “sell the news” component at play, as well as the evolving landscape for GLP-1 studies and some “misleading” cross-trial comparisons to Phase 3 data from Eli Lilly (LLY) and Novo Nordisk (NVO). The firm, which believes that VK2735 has demonstrated competitive efficacy at both mid and high doses and has a “clear opportunity to balance efficacy with tolerability,” reiterates a Buy rating and $102 price target on Viking shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
- Positive Buy Rating for Viking Therapeutics Driven by Promising VK2735 Trial Results and Market Potential
- Viking Therapeutics falls -40.1%
- Morning Movers: Nexstar and Tegna jump following merger deal
- Eli Lilly, Novo Nordisk up 2% each after Viking obesity pill trial results